Immunologic Signatures of SARS-CoV-2 Vaccination and Disease
Immunologic Signatures of SARS-CoV-2 Vaccination and Disease
批准号:
10855012
负责人:
Dan H. Barouch
金额:
$89.77万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
已结题
起止时间:
2020-09-30 至 2024-11-30
关键词:
2019-nCoVAntibodiesAntibody ResponseAntibody titer measurementAutomobile DrivingCOVID-19 pandemicCOVID-19 therapeuticsCOVID-19 vaccinationCOVID-19 vaccineCessation of lifeClinicalCollaborationsCoronavirusDataDevelopmentDiseaseDisease OutcomeDoseEuropeHumanHumoral ImmunitiesImmuneImmunityImmunologicsIndividualInfectionInfection ControlInstitutionInterventionIsraelKineticsKnowledgeMacaca mulattaMediatingMedical centerPhasePopulationResolutionSARS-CoV-2 antibodySARS-CoV-2 immunitySARS-CoV-2 infectionSARS-CoV-2 spike proteinScheduleScienceSerologyUnited StatesVaccinatedVaccinationVaccine Clinical TrialVaccineeVaccinesantigen bindingefficacy testingfollow-upinsightmanufactureneutralizing antibodynonhuman primatepost SARS-CoV-2 infectionpreventsuccesstransmission processvaccine developmentvector-based vaccine
中文摘要
摘要
研发SARS-CoV-2疫苗可能是结束新冠肺炎大流行的关键。然而,a
知识方面的关键差距是缺乏对人类SARS-CoV-2免疫相关因素的了解。
我们的初步数据表明,抗体与非人类接种疫苗后的保护相关。
灵长类动物和独特的抗体功能谱似乎可以预测自然感染的疾病结局
人类。我们的数据还表明,抗体图谱正在趋同,包括抗原结合域驱动
中和和Fc介导的效应器功能驱动保护性免疫。知识的另一个缺口是
人类感染SARS-CoV-2和接种疫苗后保护性免疫的持久性未知。
我们的初步数据表明,在人类感染SARS-CoV-2后,抗体效价可能会迅速下降,
但需要更大规模的研究和更长时间的随访来确定恢复期抗体反应的动力学。
个人。此外,疫苗引发的抗体反应的持久性仍有待确定。
我们假设康复期和接种疫苗的人都会产生功能性抗体。
与恒河猴抗SARS-CoV-2挑战的疫苗保护相关的签名。
我们进一步假设,接种疫苗将产生比诱导的抗体更持久的抗体。
通过自然感染,可以定义耐受性的免疫学相关性。
具体目标1.确定感染SARS-CoV-2或接种疫苗后相关的抗体谱
有保护的人。我们将剖析SARS-CoV-2感染者所引发的功能性抗体反应
以及在接种SARS-CoV-2疫苗的个体中提供对保护相关因素的洞察。
特定目的2.确定SARS-CoV-2抗体反应持久性的免疫学相关性
在感染或接种疫苗之后。我们将比较SARS诱导的抗体反应的持久性-
CoV-2感染和接种的个体,我们将定义耐受性的免疫学相关性。
英文摘要
ABSTRACT
The development of a SARS-CoV-2 vaccine may be critical to ending the COVID-19 pandemic. However, a
critical gap in knowledge is the lack of understanding of correlates of SARS-CoV-2 immunity in humans.
Our preliminary data suggest that antibodies correlate with protection following vaccination in nonhuman
primates and that unique antibody functional profiles appear to predict disease outcome in natural infection in
humans. Our data also point to a converging antibody profile, including both the antigen-binding domain driving
neutralization and Fc-mediated effector functions driving protective immunity. Another gap in knowledge is the
unknown durability of protective immunity following SARS-CoV-2 infection and vaccination in humans.
Our preliminary data suggest that antibody titers may wane quickly following SARS-CoV-2 infection in humans,
but larger studies and longer follow-up are needed to define the kinetics of antibody responses in convalescent
individuals. Moreover, the durability of vaccine-elicited antibody responses remains to be determined.
We hypothesize that both convalescent and vaccinated humans will develop the functional antibody
signature that correlates with vaccine protection against SARS-CoV-2 challenge in rhesus macaques.
We further hypothesize that vaccination will induce antibodies with greater durability than those induced
by natural infection and that an immunologic correlate of durability can be defined.
Specific Aim 1. Define the antibody profiles following SARS-CoV-2 infection or vaccination that correlate
with protection. We will dissect the functional antibody responses elicited in SARS-CoV-2 infected individuals
and in SARS-CoV-2 vaccinated individuals to provide insight into correlates of protection.
Specific Aim 2. Define the immunologic correlates of durability of SARS-CoV-2 antibody responses
following infection or vaccination. We will compare the durability of antibody responses induced in SARS-
CoV-2 infected and vaccinated individuals, and we will define an immunologic correlate of durability.
期刊论文(18)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
10.1016/j.medj.2022.01.004
发表时间:
2022-03-11
期刊:
Med (New York, N.Y.)
影响因子:
--
作者:
[Cobb RR, Nkolola J, Gilchuk P, Chandrashekar A, Yu J, House RV, Earnhart CG, Dorsey NM, Hopkins SA, Snow DM, Chen RE, VanBlargan LA, Hechenblaickner M, Hoppe B, Collins L, Tomic MT, Nonet GH, Hackett K, Slaughter JC, Lewis MG, Andersen H, Cook A, Diamond MS, Carnahan RH, Barouch DH, Crowe JE Jr]
通讯作者:
Crowe JE Jr
DOI:
10.1038/s41467-023-42559-x
发表时间:
2023-10-23
期刊:
NATURE COMMUNICATIONS
影响因子:
16.6
作者:
[Aid, Malika, Stephenson, Kathryn E., Collier, Ai-ris Y., Nkolola, Joseph P., Michael, James V., Mckenzie, Steven E., Barouch, Dan H.]
通讯作者:
Barouch, Dan H.
DOI:
10.1038/s41586-021-04231-6
发表时间:
2022-01
期刊:
Nature
影响因子:
64.8
作者:
[Gebre MS, Rauch S, Roth N, Yu J, Chandrashekar A, Mercado NB, He X, Liu J, McMahan K, Martinot A, Martinez DR, Giffin V, Hope D, Patel S, Sellers D, Sanborn O, Barrett J, Liu X, Cole AC, Pessaint L, Valentin D, Flinchbaugh Z, Yalley-Ogunro J, Muench J, Brown R, Cook A, Teow E, Andersen H, Lewis MG, Boon ACM, Baric RS, Mueller SO, Petsch B, Barouch DH]
通讯作者:
Barouch DH
DOI:
10.1126/scitranslmed.abo6160
发表时间:
2022-10-05
期刊:
Science translational medicine
影响因子:
17.1
作者:
[]
通讯作者:
DOI:
10.1146/annurev-med-012621-102252
发表时间:
2022-01-27
期刊:
Annual review of medicine
影响因子:
10.5
作者:
[Jacob-Dolan C, Barouch DH]
通讯作者:
Barouch DH
共 8 条
NHP Core
-
批准号:10724223
-
项目类别:
-
资助金额:$28.54万
-
财政年份:2023
-
负责人:Dan H. Barouch
-
依托单位:
Multi-Omics Analysis of Broadly Neutralizing Antibodies and Therapeutic Vaccination
-
批准号:10724219
-
项目类别:
-
资助金额:$141.27万
-
财政年份:2023
-
负责人:Dan H. Barouch
-
依托单位:
Administrative Core
-
批准号:10724220
-
项目类别:
-
资助金额:$15.5万
-
财政年份:2023
-
负责人:Dan H. Barouch
-
依托单位:
Multi-Omics Correlates of Broadly Neutralizing Antibody Efficacy
-
批准号:10724224
-
项目类别:
-
资助金额:$23.25万
-
财政年份:2023
-
负责人:Dan H. Barouch
-
依托单位:
CoVPN LOC Cross-Protocol Infrastructure Supplement for GY15 and GY16
-
批准号:10571201
-
项目类别:
-
资助金额:$532.4万
-
财政年份:2022
-
负责人:Dan H. Barouch
-
依托单位:
Project 2: Analysis of Reservoir Dynamics in SIV-Infected Rhesus Macaques
-
批准号:10599365
-
项目类别:
-
资助金额:$69.64万
-
财政年份:2022
-
负责人:Dan H. Barouch
-
依托单位:
Project 2: Analysis of Reservoir Dynamics in SIV-Infected Rhesus Macaques
-
批准号:10459662
-
项目类别:
-
资助金额:$40.12万
-
财政年份:2022
-
负责人:Dan H. Barouch
-
依托单位:
HIV Vaccines Clinical Trials Network Leadership and Operations Center
-
批准号:10311601
-
项目类别:
-
资助金额:$4312.46万
-
财政年份:2021
-
负责人:Dan H. Barouch
-
依托单位:
I4C 2.0: Immunotherapy for Cure
-
批准号:10469460
-
项目类别:
-
资助金额:$467.78万
-
财政年份:2021
-
负责人:Dan H. Barouch
-
依托单位:
I4C 2.0: Immunotherapy for Cure
-
批准号:10311894
-
项目类别:
-
资助金额:$490.47万
-
财政年份:2021
-
负责人:Dan H. Barouch
-
依托单位:
CoVPN 3005 - Efficacy, Immunogenicity, and Safety of SARS-CoV-2 Recombinant Protein Vaccine with Adjuvant in Adults 18 Years of Age and Older
-
批准号:10415762
-
项目类别:
-
资助金额:$6142.91万
-
财政年份:2021
-
负责人:Dan H. Barouch
-
依托单位:
I4C 2.0: Immunotherapy for Cure
-
批准号:10615238
-
项目类别:
-
资助金额:$467.0万
-
财政年份:2021
-
负责人:Dan H. Barouch
-
依托单位:
Single-Cell Analysis of the HIV/SIV Reservoir
-
批准号:9892744
-
项目类别:
-
资助金额:$83.99万
-
财政年份:2020
-
负责人:Dan H. Barouch
-
依托单位:
Single-Cell Analysis of the HIV/SIV Reservoir
-
批准号:10406264
-
项目类别:
-
资助金额:$82.11万
-
财政年份:2020
-
负责人:Dan H. Barouch
-
依托单位:
Single-Cell Analysis of the HIV/SIV Reservoir
-
批准号:10188413
-
项目类别:
-
资助金额:$82.11万
-
财政年份:2020
-
负责人:Dan H. Barouch
-
依托单位:
Ad26 Based Therapeutic Vaccines for HIV
-
批准号:10399642
-
项目类别:
-
资助金额:$150.39万
-
财政年份:2020
-
负责人:Dan H. Barouch
-
依托单位:
Single-Cell Analysis of the HIV/SIV Reservoir
-
批准号:10840033
-
项目类别:
-
资助金额:$43.23万
-
财政年份:2020
-
负责人:Dan H. Barouch
-
依托单位:
Single-Cell Analysis of the HIV/SIV Reservoir
-
批准号:10634684
-
项目类别:
-
资助金额:$82.11万
-
财政年份:2020
-
负责人:Dan H. Barouch
-
依托单位:
Ad26 Based Therapeutic Vaccines for HIV
-
批准号:10163123
-
项目类别:
-
资助金额:$150.43万
-
财政年份:2020
-
负责人:Dan H. Barouch
-
依托单位:
Immunologic Signatures of SARS-CoV-2 Vaccination and Disease
-
批准号:10688351
-
项目类别:
-
资助金额:$72.54万
-
财政年份:2020
-
负责人:Dan H. Barouch
-
依托单位:
海外基金